Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP for drug discovery and mechanism of action (MOA) research

Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sotatercept is a fusion protein contains extracellular domain of the human activin receptor type IIA fused with the Fc domain of human IgG1. Sotatercept acts as a ligand trap for members of the TGF-β superfamily, thus restoring balance between the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway. Sotatercept has been used to treat hematologic disorders, dysfunctional TGF-β superfamily signaling pathway based bone loss, chemotherapy-induced anemia, multiple myeloma, myelodysplastic syndromes, β-thalassemia, and end-stage kidney disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-998-1mg	1mg	3090
GMP-Bios-INN-998-10mg	10mg	Inquiry
GMP-Bios-INN-998-100mg	100mg	Inquiry
GMP-Bios-INN-998-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP
INN Name	Sotatercept
Target	INHBA/ACT
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [ACVR2A (activin A receptor type IIA, ActR-II, ActRIIA)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [ACVR2A (activin A receptor type IIA, ActR-II, ActRIIA)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Celgene corporation (Summit USA) / Acceleron Pharma, Inc (Cambridge UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0